| 08/15 | Enhertu Significantly Delayed Breast Cancer Progression in Trial, AstraZeneca Says | DJ |
| 08/15 | H.U. Group Holdings, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023 | CI |
| 08/15 | ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer | CI |
| 08/15 | Abingdon Health plc Announces Resignation of Lyn Rees as Non-Executive Director At the End of September 2022 | CI |
| 08/15 | H.U. Group Holdings, Inc. Provides Dividend Guidance for the Second Quarter and for the Fiscal Year Ended March 31, 2023 | CI |
| 08/15 | Abingdon Health plc Provides Earnings Guidance for the Full Year 2022 | CI |
| 08/15 | Novartis says lung cancer drug canakinumab failed phase III trial | RE |
| 08/15 | Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer | DJ |
| 08/15 | Novartis Provides Update on Phase III CANOPY-A Study Evaluating Canakinumab as Adjuvant Treatment in Non-Small Cell Lung Cancer | CI |
| 08/15 | Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders | DJ |
| 08/15 | Toleranzia Appoints Torbjörn Sannerstedt as New Chief Financial Officer | CI |
| 08/15 | Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders | CI |
| 08/15 | Roche Launches New Diagnostic Test for the Better Understanding of Immune Response to SARS-CoV-2 | CI |
| 08/15 | Medivolve Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 | CI |
| 08/15 | StageZero Life Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 | CI |
| 08/15 | Rachanee Yingchairak agreed to acquire Princeton Park Suites Company Limited from Vibhavadi Medical Center Public Company Limited for THB 20 million. | CI |
| 08/15 | Proteomics International Laboratories Limited announced that it expects to receive AUD 7.9985 million in funding | CI |
| 08/15 | DELTA 9 CANNABIS INC. (TSX : DN) entered into an asset purchase agreement to acquire all or Substantially all assets of 10552763 Canada Corp. for CAD 3.25 million. | CI |
| 08/15 | Kubota Pharmaceutical Holdings Co., Ltd. announced that it expects to receive ¥3.1 million in funding from Barclays Bank PLC, Investment Arm | CI |
| 08/15 | Boston Scientific Corporation acquired Obsidio, Inc. | CI |
| 08/15 | Sonnet BioTherapeutics Holdings, Inc. announced that it has received $2.25 million in funding | CI |
| 08/15 | Plus Therapeutics, Inc. authorizes a Buyback Plan. | CI |
| 08/15 | Irwin Naturals Inc. acquired Assets from Hobie Fuerstman DO PLC. | CI |
| 08/15 | Hbm Holdings Limited Announces Completion of First Dosing of Last Patient with Hbm4003 Phase Ib Trial | CI |
| 08/15 | TRANSCRIPT : Caladrius Biosciences, Inc. - Special Call | CI |
| 08/15 | Certain Series B Preferred Stock of Sunshine Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 15-AUG-2022. | CI |
| 08/15 | Certain Convertible Notes of Sunshine Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 15-AUG-2022. | CI |
| 08/15 | 56,160 Ordinary Shares of Biome Australia Limited are subject to a Lock-Up Agreement Ending on 15-AUG-2022. | CI |
| 08/15 | Certain Common Stock of Sunshine Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 15-AUG-2022. | CI |
| 08/15 | EVOFEM BIOSCIENCES, INC.(OTCPK : EVFM) dropped from S&P TMI Index | CI |
| 08/15 | RADIUS HEALTH, INC.(NASDAQGM : RDUS) dropped from S&P Biotechnology Select Industry Index | CI |
| 08/15 | RADIUS HEALTH, INC.(NASDAQGM : RDUS) dropped from S&P Global BMI Index | CI |
| 08/15 | RADIUS HEALTH, INC.(NASDAQGM : RDUS) dropped from S&P TMI Index | CI |
| 08/14 | Novartis Phase 3 Canopy-A Trial Didn't Meet Primary Endpoint | DJ |
| 08/14 | MGC Pharmaceuticals Ltd Provides the Following Results from A Recently Completed Randomised, Double Blind, Placebo Controlled Study Investigating the Effect of MGC's Pharma's Epilepsy Treatment, Cannepil®, on Vehicle Driving Performance, Sedation and Mood | CI |
| 08/14 | United Orthopedic Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 | CI |
| 08/14 | Daiichi Sankyo Shares Gain After It Wins Dispute Over Cancer Drug Technology | DJ |
| 08/14 | Global Health Limited Appoints Robin Armstrong as Regional Chief Executive, Asia Pacific in Singapore | CI |
| 08/14 | Wattana Karnpaet Public Company Limited Announces Board Changes | CI |
| 08/14 | Wattana Karnpaet Public Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 | CI |
| 08/14 | Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD | CI |
| 08/14 | Chularat Hospital Public Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 | CI |
| 08/14 | Careteq Limited Announces Exclusive Agreement with StrongRoom AI | CI |
| 08/14 | Astra Industrial Group Company Reports Earnings Results for the Second Quarter Ended June 30, 2022 | CI |
| 08/14 | Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2022 | CI |
| 08/14 | ChengDa Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 | CI |
| 08/14 | Medtecs International Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2022 | CI |
| 08/14 | Clearbridge Health Limited Reports Earnings Results for the Half Year Ended June 30, 2022 | CI |
| 08/14 | Innovative Eyewear, Inc. has completed an IPO in the amount of $8.382354 million. | CI |
| 08/13 | Q & M Dental Group Limited Declares No Dividend for the Second Quarter Ended 30 June 2022 | CI |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Prev.
